Duman R S
Division of Molecular Psychiatry, Abraham Ribicoff Research Facilities, Connecticut Mental Health Center, Yale University School of Medicine, New Haven, CT, USA.
Mol Psychiatry. 2002;7 Suppl 1:S29-34. doi: 10.1038/sj.mp.4001016.
Recent studies demonstrate that the molecular elements known to regulate neuronal plasticity in models of learning and memory are also involved in the actions of drugs used for the treatment of depression and bipolar disorder. This includes up-regulation of transcription factors, such as the cAMP response element binding protein and neurotrophic factors, such as brain derived neurotrophic factor. These findings raise the possibility that regulation of neural plasticity in specific neuronal circuits is integrally involved in the therapeutic intervention of mood disorders. Atypical antipsychotic drugs, including clozapine and olanzapine, are also effective for the treatment of bipolar disorder, and are used as add-on medication for unipolar depression. The possibility that these atypical antipsychotic drugs also influence the molecular determinants of synaptic plasticity that are involved in the response to drugs used for the treatment of mood disorders, is discussed.
近期研究表明,在学习和记忆模型中已知调节神经元可塑性的分子元件,也参与了用于治疗抑郁症和双相情感障碍的药物作用。这包括转录因子的上调,如环磷腺苷反应元件结合蛋白,以及神经营养因子,如脑源性神经营养因子。这些发现增加了一种可能性,即特定神经元回路中神经可塑性的调节在情绪障碍的治疗干预中起着不可或缺的作用。非典型抗精神病药物,包括氯氮平和奥氮平,对双相情感障碍的治疗也有效,并被用作单相抑郁症的附加药物。本文讨论了这些非典型抗精神病药物是否也会影响参与情绪障碍治疗药物反应的突触可塑性分子决定因素。